Ranbaxy Laboratories

ICGEB and Sun Pharma sign agreement to develop botanical drug to treat dengue

ICGEB will provide the technical know-how and pre-clinical expertise and Sun Pharma to develop this drug with appropriate pre-clinical & clinical studies to register it in India and other global markets

Sun completes sale of two Ranbaxy divisions to Strides Shasun

The agreement involved transfer of these two marketing divisions, along with employees to Strides, for Rs 165 crore Sun Pharmaceutical Industries has completed the process of selling two divisions of erstwhile Ranbaxy Laborat

Cipher, Ranbaxy settle patent litigation with Actavis

Cipher Pharma Inc, along with partners Ranbaxy - a Sun Pharma firm - and Galephar Pharmaceutical Research, has entered into a patent litigation settlement with Actavis...

Cipher, Ranbaxy settle patent litigation with Actavis

Sun Pharma to sell Ranbaxy’s 2 CNS divisions to Strides Arcolab for Rs 165 crore

Sun Pharma is selling erstwhile Ranbaxy's two divisions 'Solus' and 'Solus Care' divisions in central nervous system (CNS) segment in India to Strides Arcolab for Rs 165 crore.

Sun Pharma to sell Ranbaxy’s 2 CNS divisions to Strides Arcolab for Rs 165 crore

Sun Pharma looking to divest Ireland plant

The company is trying to control costs that have spiralled since it bought Ranbaxy Laboratories Sun Pharmaceutical Industries is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiral

Sun Pharma posts net profit of Rs 479 crores Q1FY16

Net sales has been registered at Rs 6,522 crores Sun Pharmaceutical Industries has posted its financials for first quarter ending June 30, 2015. The financials for Q1FY16 include several one-time and exceptional charges relat

Integration with Ranbaxy may hit Sun Pharma profit

The country’s largest drugmaker Sun Pharmaceutical said it expects consolidated profit for FY16 to be adversely impacted...

Sun Pharma asks 18 top Ranbaxy executives to leave

Those who have been asked to resign are Indrajit Banerjee, President and CFO; Yugal Sikri, country head (India) Ranbaxy; Maninder Singh, V-P marketing; Govind Jaju, global head, sourcing; Ratul Bahaduri, director-finance; amo

Sun Pharma asks 18 top Ranbaxy executives to leave

For Daiichi, side effects of Ranbaxy refuse to wane

Clause may hold it liable for penalty payout of $325 million

After the fall, Sun Pharma shares rebound on value buying, rise 3 pct

Stocks of Sun Pharmaceutical made a comeback at the bourses today, rising nearly 3 per cent, a day after Japanese drugmaker Daiichi Sankyo sold its entire stake of around 9 per cent in the company for Rs 20,025 crore.

After the fall, Sun Pharma shares rebound on value buying, rise 3 pct

Daiichi’s $3.6 bn exit from Sun Pharmaceutical hits rupee, stocks

Concerns about foreign outflows weigh after Japan's Daiichi Sankyo's $3.6 billon share sale in Sun Pharmaceutical Industries.

Daiichi’s $3.6 bn exit from Sun Pharmaceutical hits rupee, stocks

Japan’s Daiichi Sankyo sells Sun Pharma stake

Daiichi Sankyo said it would disclose the financial details related to the Sun Pharma stake sale when it announces results for the fiscal year that ended on March 31

RSF honours outstanding scientists

21st Annual Symposium on 'Neurodegeneration' was also held

Sun Pharma closes merger deal with Ranbaxy

The combined entity’s manufacturing footprint covers five continents with products sold in over 150 nations

Sun Pharma gets RBI nod for transfer of Ranbaxy overseas investments

Sun Pharmaceutical Industries has received RBI nod for transfer of overseas investments of Ranbaxy to it and issue its shares to the non-resident shareholders of the latter as part of their $4-billion merger deal

Ranbaxy Science Foundation honours outstanding scientists and young science scholars

Ranbaxy Science Foundation (RSF), a non-profit organisation set-up by Ranbaxy Laboratories (Ranbaxy) announced Ranbaxy Research Awards for excellence in original research work in medical and pharmaceutical sciences.

Ranbaxy loses approvals, exclusivity of 2 drugs in US

Ranbaxy Laboratories' tentative approvals for its generic versions of digestive disorder drug Nexium and antiviral Valcyte...

Ranbaxy loses approvals, exclusivity of 2 drugs in US

Sun Pharmaceutical wins US approval to buy Ranbaxy

Ranbaxy has been involved in a wrangle with the US FDA, which has barred a range of its medicines from the United States.

Sun Pharmaceutical wins US approval to buy Ranbaxy

Ranbaxy Laboratories December quarter net loss widens to Rs 1,029 cr on forex woes

Ranbaxy Laboratories today reported widening of its consolidated net loss to Rs 1,029.72 crore for the third quarter ended...

Ranbaxy Laboratories December quarter net loss widens to Rs 1,029 cr on forex woes

CCI approves Ranbaxy acquisition by Sun Pharma

Sun Pharma and Ranbaxy had filed the notice with the CCI on May 6, 2014 and sought its approval with respect to the deal

Deal clincher: Sun hoists its flag on domestic pharma landscape

Competition Commission has asked Sun Pharma to divest one drug and Ranbaxy six over the next six months to ensure competition in the market

India’ Sun Pharma, Ranbaxy gain after regulator approves deal

Sun Pharmaceutical Industries gains 2.9 pct, Ranbaxy Laboratories up 3.7 pct.

CCI clears Sun Pharma-Ranbaxy Laboratorie merger, subject to divesting seven brands

The Competition Commission of India cleared the $3.2-billion Sun Pharmaceutical Industries’ purchase of Ranbaxy Laboratories...

CCI clears $4-bn Sun Pharmaceutical, Ranbaxy Laboratories merger deal, but adds riders

The long-pending $4-billion merger between Sun Pharmaceuticals and Ranbaxy Laboratories today...

CCI clears $4-bn Sun Pharmaceutical, Ranbaxy Laboratories merger deal, but adds riders

AstraZeneca, Ranbaxy Laboratories prevail, Nexium drug deal ‘not anti-competitive’

In a landmark judgement for pharma sector, a US jury has ruled that AstraZeneca's patent litigation settlement for blockbuster drug Nexium...

AstraZeneca, Ranbaxy Laboratories prevail, Nexium drug deal ‘not anti-competitive’

RSSDI and Ranbaxy join hands to help juvenile diabetes patients

507 doctors came together to create a blue circle, the universal symbol of diabetes to spread awareness

German ban on Ranbaxy’s Dewas product expands to entire EU

Adding to Ranbaxy's regulatory troubles overseas, certain drugs produced at its Dewas plant have been barred from export...

Advertisement
Income Tax Calculator, Budget 2019, How to Calculate Income Tax

 

Stock Market

Most Read

Advertisement

Budget 2020

Advertisement

Related Articles